Przegląd Dermatologiczny

Full text

3/2026 vol. 113
Special paper

Generalized pustular psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society

Adam Reich 1
,
Marta Kołt-Kamińska 1
,
Witold Owczarek 2
,
Joanna Narbutt 3
,
Aleksandra Lesiak 3
,
Maciej Pastuszczak 4
,
Jacek C. Szepietowski 5, 6
,
Irena Walecka 7

  1. Department of Dermatology, Faculty of Medicine, University of Rzeszow, Poland

  2. Department of Dermatology, Military Institute of Medicine, National Research Institute, Warsaw, Poland

  3. Department of Dermatology, Pediatric Dermatology and Oncology, Laboratory of Autoinflammatory, Genetic and Rare Skin Disorders, Medical University of Lodz, Poland

  4. Department of Dermatology in Zabrze, Silesian Medical University in Katowice, Poland

  5. Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wroclaw University of Science and Technology, Wrocław, Poland

  6. Department of Dermato-Venereology, 4th Military Hospital, Wroclaw, Poland

  7. Department of Dermatology, Centre of Postgraduate Medical Education, National Institute of Medicine of the Ministry of Interior and Administration, Warsaw, Poland

Dermatol Rev/Przegl Dermatol 2026, 113, 113–130

DOI: https://doi.org/10.5114/dr.2026.164388
Data publikacji online: 2026/09/09
Article file
Generalized Pustular.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Navarini A.A., Burden A.D., Capon F., Mrowietz U., Puig L., Köks S., et al.: European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol 2017, 31, 1792-1799.
  2. Gooderham M.J., Van Voorhees A.S., Lebwohl M.G., Korman N.J., Gelfand J.M., Strober B., et al.: Generalized pustular psoriasis: epidemiology, clinical presentation, and burden of disease. J Am Acad Dermatol 2022, 86, 102-111.
  3. Marrakchi S., Puig L.: Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol 2022, 23 Suppl 1, 13-19.
  4. Bachelez H.: Pustular psoriasis and related pustular skin diseases. Br J Dermatol 2018, 178, 614-618.
  5. Gooderham M.J., Krueger J.G., Papp K.A., Menter A., Reich K., Puig L., et al.: Updated epidemiology and treatment landscape of generalized pustular psoriasis. Dermatol Ther 2023, 36, e15701.
  6. Onoufriadis A., Simpson M.A., Pink A.E., Di Meglio P., Smith C.H., Pullabhatla V, et al.: Mutations in IL36RN, CARD14 and AP1S3 in patients with generalized pustular psoriasis. J Invest Dermatol 2018, 138, 386-393.
  7. Choon S.E., Foley P.A., Asawanonda P., Fujita H., Jo S.J., Shi Y.L., et al.: Asia-Pacific consensus recommendations on the management of generalized pustular psoriasis. J Dermatol 2024, 51, 1579-1595.
  8. Twiss J., Shim T.N., Langan S.M., Snowball J., McFarlane L., Smith C.H.: Epidemiology of generalized pustular psoriasis in Europe. Br J Dermatol 2019, 181, 728-736.
  9. Ohata C., Ishii N., Hashimoto T.: Epidemiology and clinical characteristics of pustular psoriasis in East Asia. J Dermatol Sci 2020, 98, 85-90.
  10. Szepietowski J.C., Reich A., Adamski Z., Błaszczyk M., Kaszuba A., Wojas-Pelc A., et al.: Epidemiologia rzadkich postaci łuszczycy w Europie Środkowo-Wschodniej. Dermatol Rev 2021, 108, 253-262.
  11. Bachelez H.: Pustular psoriasis: the dawn of a new era. Acta Derm Venereol 2020, 100, adv00034.
  12. Marrakchi S., Guigue P., Renshaw B.R., Puel A., Pei X.Y., Fraitag S., et al.: Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011, 365, 620-628.
  13. Choon S.E., van de Kerkhof P., Gudjonsson J.E., de la Cruz C., Barker J., Morita A., et al.: International consensus definition and diagnostic criteria for generalized pustular psoriasis from the International Psoriasis Council. JAMA Dermatol 2024, 160, 758-768.
  14. Bissonnette R., Papp K.A., Gooderham M., Girard G., Puig L., Strober B., et al.: Assessment tools and clinical endpoints in generalized pustular psoriasis. J Am Acad Dermatol 2021, 84, 1596-1604.
  15. Johnston A., Xing X., Wolterink L., Barnes D.H., Yin Z., Reingold L., et al.: IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol 2017, 140, 109-120.
  16. Uppala R., Tsoi L.C., Harms P.W., Wang B., Billi A.C., Maverakis E., et al.: “Autoinflammatory psoriasis” – genetics and biology of pustular psoriasis. Cell Mol Immunol 2021, 18, 307-317.
  17. Young K.Z., Sarkar M.K., Gudjonsson J.E.: Pathophysiology of generalized pustular psoriasis. Exp Dermatol 2023, 32, 1194-1203.
  18. Benezeder T., Wolf P., Hoetzenecker W.: Histopathologic differentiation of generalized pustular psoriasis and acute generalized exanthematous pustulosis. Am J Dermatopathol 2025, 47, 12-20.
  19. Bassoy E.Y., Towne J.E., Gabay C.: Regulation and function of interleukin-36 cytokines. Immunol Rev 2018, 281, 169-178.
  20. Baum P., Visvanathan S., Garcet S., Roy J., Schmid R., Bossert S., et al.: Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis. J Allergy Clin Immunol 2022, 149, 1402-1412.
  21. Hussain S., Berki D.M., Choon S.E., Burden A.D., Allen M.H., Arostegui J.I., et al.: IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol 2015, 135, 1067-1070.e9.
  22. Twelves S., Mostafa A., Dand N., Burri E., Farkas K., Wilson R., et al.: Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol 2019, 143, 1021-1026.
  23. Bachelez H., Choon S.E., Marrakchi S., Burden A.D., Tsai T.F., Morita A., et al.: Trial of spesolimab for generalized pustular psoriasis. N Engl J Med 2021, 385, 2431-2440.
  24. Bachelez H., Choon S.E., Marrakchi S., Burden A.D., Tsai T.F., Morita A., et al.: Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med 2019, 380, 981-983.
  25. Smieszek S., Przychodzen B., Tyner C., Johnson C., Bushman M., Brzezynski J., et al.: Efficacy and safety of imsidolimab for generalized pustular psoriasis. NEJM Evid 2026, 5, EVIDoa2500272.
  26. Strober B., Krueger J.G., Puig L., Papp K.A., Reich K., Gordon K.B., et al.: Clinical management and outcome measures in generalized pustular psoriasis. Br J Dermatol 2022, 187, 175-186.
  27. Burden A.D., Bissonnette R., Lebwohl M.G., Gloede T., Anatchkova M., Budhiarso I., et al.: Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI). J Eur Acad Dermatol Venereol 2023, 37, 1327-1335.
  28. Fujita H., Terui T., Hayama K., Akiyama M., Ikeda S., Mabuchi T., et al.: Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol 2018, 45, 1235-1270.
  29. Navarini A.A., Pagotto A., Langford B., Gradl B., Van De Kerkhof P.: Mortality, prevalence, comorbidity, and flare patterns in generalised pustular psoriasis: a comprehensive literature review. Eur J Dermatol 2025, 35, 459-470.
  30. Rivera-Díaz R., Daudén E., Carrascosa J.M., Cueva P., Puig L.: Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment. Dermatol Ther 2023, 13, 673-688.
  31. Kara Polat A., Alpsoy E., Kalkan G., Aytekin S., Uçmak D., Yasak Güner R., et al.: Sociodemographic, clinical, laboratory, treatment and prognostic characteristics of 156 generalized pustular psoriasis patients in Turkey: a multicentre case series. J Eur Acad Dermatol Venereol 2022, 36, 1256-1265.
  32. Kołt-Kamińska M., Marek-Józefowicz L., Krajewski P., Nowowiejska J., Siekierko A., Duchnik E., et al.: Characteristics of patients with generalized pustular psoriasis: a report of the Polish Generalized Pustular Psoriasis Group. Dermatol Ther 2024, 14, 3379-3393.
  33. Choon S.E., Lai N.M., Mohammad N.A., Nanu N.M., Tey K.E., Chew S.F.: Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2014, 53, 676-684.
  34. Noe M.H., Wan M.T., Mostaghimi A., Gelfand J.M.; Pustular Psoriasis in the US Research Group. Evaluation of a case series of patients with generalized pustular psoriasis in the United States. JAMA Dermatol 2022, 158, 73-78.
  35. Wolf P., Ceovic R., Conrad C., Falkensteiner K., Graier T., Kołt-Kamińska M., et al.: Characteristics and management of generalized pustular psoriasis (GPP): experience from the Central and Eastern Europe (CEE) GPP Expert Network. J Eur Acad Dermatol Venereol 2024, 38, 1531-1542.
  36. Mrowietz U., van de Kerkhof P.C.M., Puig L.: Systemic inflammation and organ involvement in generalized pustular psoriasis. J Eur Acad Dermatol Venereol 2022, 36, 1201-1209.
  37. Krueger J.G., Puig L., Thaçi D.: Targeting innate immunity in pustular psoriasis. Lancet 2023, 401, 120-132.
  38. Robinson A., Van Voorhees A.S., Hsu S., Korman N.J., Lebwohl M.G., Bebo B.F. Jr, et al.: Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012, 67, 279-288.
  39. Ozawa A., Ohkido M., Haruki Y., Kobayashi H., Ohkawara A., Ohno Y., et al.: Treatments of generalized pustular psoriasis: a multicenter study in Japan. J Dermatol 1999, 26, 141-149.
  40. Chen X., Chen Y., Wang J., Li L., Zheng J.: Systemic retinoids in pustular psoriasis: a retrospective analysis. Int J Dermatol 2018, 57, 348-354.
  41. David M., Hodak E., Lowe N.J.: Adverse effects of retinoids. Med Toxicol Adverse Drug Exp 1988, 3, 273-288.
  42. Haustein U.F., Rytter M.: Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol 2000, 14, 382-388.
  43. Meinardi M.M., Westerhof W., Bos J.D.: Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A. Br J Dermatol 1987, 116, 269-270.
  44. Kiliç A., Güleç A.T., Kiliç S., Gül U.: Cyclosporine treatment in generalized pustular psoriasis. Int J Dermatol 2001, 40, 470-473.
  45. Ji J., Shu D., Zheng M., Wang Y., Chen J.: Non-biologic systemic therapies in pustular psoriasis. Dermatology 2011, 223, 37-42.
  46. Kromer C., Loewe E., Schaarschmidt M.L., Pinter A., Gerdes S., Herr R., et al.: Drug survival in the treatment of generalized pustular psoriasis: a retrospective multicenter study. Dermatol Ther 2021, 34, e14814.
  47. Weishaupt C., Metze D., Luger T.A., Ständer S.: Treatment of pustular psoriasis with infliximab. J Dtsch Dermatol Ges 2007, 5, 397-399.
  48. Kołt-Kamińska M., Żychowska M., Reich A.: Infliximab in combination with low-dose acitretin in generalized pustular psoriasis: a report of two cases and review of the literature. Biologics 2021, 15, 317-327.
  49. Zelickson B.D., Muller S.A.: Generalized pustular psoriasis in childhood: report of thirteen cases. J Am Acad Dermatol 1991, 24, 186-194.
  50. Umezawa Y., Ozawa A., Kawasima T., Shimizu H., Terui T., Tagami H., et al.: Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res 2003, 295 Suppl 1, S43-S54.
  51. Dadlani C., Orlow S.J.: Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literature. J Am Acad Dermatol 2005, 52, 316-340.
  52. Kaur I., Dogra S., De D., Kanwar A.J.: Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatol 2008, 25, 184-188.
  53. Dogra S., Handa S., Kanwar A.J.: Methotrexate in severe childhood psoriasis. Pediatr Dermatol 2004, 21, 283-284.
  54. Dogra S., Kumaran M.S., Handa S., Kanwar A.J.: Methotrexate for generalized pustular psoriasis in a 2-year-old child. Pediatr Dermatol 2005, 22, 85-86.
  55. Amor K.T., Ryan C., Menter A.: The use of cyclosporine in dermatology: part I. J Am Acad Dermatol 2010, 63, 925-946.
  56. Mahé E., Bodemer C., Pruszkowski A., Teillac-Hamel D., de Prost Y.: Cyclosporine in childhood psoriasis. Arch Dermatol 2001, 137, 1532-1533.
  57. Kiliç S.S., Hacimustafaoğlu M., Celebi S., Karadeniz A., Ildirim I.: Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol 2001, 18, 246-248.
  58. Alli N., Güngör E., Karakayali G., Lenk N., Artüz F.: The use of cyclosporin in a child with generalized pustular psoriasis. Br J Dermatol 1998, 139, 754-755.
  59. Robinson A., Van Voorhees A.S., Hsu S., Korman N.J., Lebwohl M.G., Bebo B.F. Jr, et al.: Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012, 67, 279-288.
  60. Pereira T.M., Vieira A.P., Fernandes J.C., Antunes H., Sousa Basto A.: Anti-TNF-αlpha therapy in childhood pustular psoriasis. Dermatology 2006, 213, 350-352.
  61. Fialová J., Vojáčková N., Vaňousová D., Hercogová J.: Juvenile generalized pustular psoriasis treated with etanercept. Dermatol Ther 2014, 27, 105-108.
  62. Cuperus E., Koevoets R., van der Smagt J.J., Toonstra J., de Graaf M., Frenkel J., et al.: Juvenile interleukin-36 receptor antagonist deficiency (DITRA) with c.80T>C (p.Leu27Pro) mutation successfully treated with etanercept and acitretin. JAAD Case Rep 2018, 4, 192-195.
  63. Alvarez A.C., Rodríguez-Nevado I., de Argila D., Rubio F.P., Rovira I., Torrelo A., et al.: Recalcitrant pustular psoriasis successfully treated with adalimumab. Pediatr Dermatol 2011, 28, 195-197.
  64. Du Y., Yan Q., Chen M., Dong Z., Wang F.: Efficacy of adalimumab in pediatric generalized pustular psoriasis: case series and literature review. J Dermatolog Treat 2022, 33, 2862-2868.
  65. Ho P.H., Tsai T.F.: Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: a case report and review of published work. J Dermatol 2018, 45, 1353-1356.
  66. López-Sánchez C., Falla L.M., Roé-Crespo E., Arostegui J.I., Mozos A., Bernal S., et al.: Excellent response to secukinumab in an infant with severe generalized pustular psoriasis. J Dermatol 2021, 48, 907-910.
  67. Albela H., Begum S., Leong K.F.: Successful treatment of paediatric generalized pustular psoriasis with secukinumab: a case series. J Dermatolog Treat 2022, 33, 1769-1773.
  68. Zhu H., Song P., Du D., Tian H.: Successful treatment of a 3-year-old girl with generalized pustular psoriasis using secukinumab monotherapy. Pediatr Dermatol 2021, 38, 1366-1367.
  69. Guo J., Wang B., Zhang Z.Y.: Rapid response to secukinumab in a 5-year-old with deficiency of the interleukin-36 receptor antagonist (DITRA) with severe scalp and nail involvement. Pediatr Dermatol 2021, 38, 1258-1263.
  70. Posso-De Los Rios C.J., Pope E., Lara-Corrales I.: A systematic review of systemic medications for pustular psoriasis in pediatrics. Pediatr Dermatol 2014, 31, 430-439.
Copyright: © 2026 Polish Dermatological Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Indeks osobowy
Share
without publication fees
without publication fees
Coverage in
Integrated with
plagiat pl
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications